Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Income from Continuing Operations (2020 - 2023)

Historic Income from Continuing Operations for Therapeutics (RAPT) over the last 4 years, with Q4 2023 value amounting to -$33.2 million.

  • Therapeutics' Income from Continuing Operations fell 3596.25% to -$33.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$127.1 million, marking a year-over-year decrease of 4809.95%. This contributed to the annual value of -$127.1 million for FY2023, which is 4809.95% down from last year.
  • According to the latest figures from Q4 2023, Therapeutics' Income from Continuing Operations is -$33.2 million, which was down 3596.25% from -$33.9 million recorded in Q3 2023.
  • Over the past 5 years, Therapeutics' Income from Continuing Operations peaked at -$12.4 million during Q2 2020, and registered a low of -$33.9 million during Q3 2023.
  • In the last 4 years, Therapeutics' Income from Continuing Operations had a median value of -$18.8 million in 2021 and averaged -$20.9 million.
  • Per our database at Business Quant, Therapeutics' Income from Continuing Operations plummeted by 1622.97% in 2022 and then tumbled by 5646.74% in 2023.
  • Over the past 4 years, Therapeutics' Income from Continuing Operations (Quarter) stood at -$12.7 million in 2020, then plummeted by 40.79% to -$17.9 million in 2021, then tumbled by 36.27% to -$24.4 million in 2022, then crashed by 35.96% to -$33.2 million in 2023.
  • Its Income from Continuing Operations was -$33.2 million in Q4 2023, compared to -$33.9 million in Q3 2023 and -$28.4 million in Q2 2023.